NCT06885697View on ClinicalTrials.gov

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

June 1, 2034

Study Completion Date

June 1, 2044

Conditions
MesotheliomaNeoplasmsStomach NeoplasmsPancreatic NeoplasmsOvarian NeoplasmsLung NeoplasmsThymus NeoplasmsColonic Neoplasms
Interventions
DEVICE

mesothelin expression testing

Assay done at screening to determine mesothelin expression levels

BIOLOGICAL

TNhYP217 CAR T Cells

Variable doses, administered intravenously on Day 0

DRUG

fludarabine

30 mg/m\^2 IV infusion administered followed by cyclophosphamide on days both are given. Daily x 4 doses on Day -7, -6, -5 and -4

DRUG

cyclophosphamide

600 mg/m\^2 IV infusion. Daily x 3 doses on Day -6, -5, -4

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH